Decitabine reverses TGF-β1-induced epithelial–mesenchymal transition in non-small-cell lung cancer by regulating miR-200/ZEB axis [Corrigendum]
Zhang N, Liu Y, Wang Y, Zhao M, Tu L, Luo F. Drug Des Devel Ther. 2017;11:969–983.
Throughout the paper, including Figures, an abbreviation has been defined incorrectly. TGF-β1 was incorrectly defined ‘tumor growth factor-beta 1’. The correct definition for TGF-β1 is ‘transforming growth factor-beta 1’.
Read the original article
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]
Other article by this author:
Decitabine reverses TGF-β1-induced epithelial–mesenchymal transition in non-small-cell lung cancer by regulating miR-200/ZEB axis
Zhang N, Liu Y, Wang Y, Zhao M, Tu L, Luo F
Published Date: 28 March 2017